Shares of Privia Health Group, Inc. (NASDAQ:PRVA - Get Free Report) have received a consensus recommendation of "Buy" from the thirteen analysts that are presently covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a hold recommendation, eleven have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 12 month target price among analysts that have issued a report on the stock in the last year is $27.77.
A number of equities analysts have recently commented on the stock. JPMorgan Chase & Co. increased their price target on shares of Privia Health Group from $29.00 to $32.00 and gave the stock an "overweight" rating in a report on Wednesday, May 28th. Needham & Company LLC reiterated a "buy" rating and issued a $30.00 target price on shares of Privia Health Group in a research report on Thursday, April 10th. Truist Financial raised their price target on Privia Health Group from $27.00 to $28.00 and gave the company a "buy" rating in a research report on Thursday, April 10th. Canaccord Genuity Group lifted their price target on Privia Health Group from $29.00 to $30.00 and gave the stock a "buy" rating in a research note on Friday, February 28th. Finally, Robert W. Baird increased their price objective on Privia Health Group from $24.00 to $26.00 and gave the company an "outperform" rating in a research report on Tuesday, April 15th.
Get Our Latest Analysis on PRVA
Privia Health Group Trading Down 1.0%
Shares of NASDAQ PRVA traded down $0.24 during midday trading on Friday, hitting $23.00. 559,809 shares of the company's stock were exchanged, compared to its average volume of 739,705. The business's fifty day moving average price is $23.40 and its two-hundred day moving average price is $22.81. The company has a market cap of $2.80 billion, a price-to-earnings ratio of 230.02, a PEG ratio of 3.47 and a beta of 0.83. Privia Health Group has a 12-month low of $16.37 and a 12-month high of $26.09.
Insider Activity
In related news, CFO David Mountcastle sold 3,322 shares of Privia Health Group stock in a transaction on Monday, May 12th. The shares were sold at an average price of $24.99, for a total value of $83,016.78. Following the transaction, the chief financial officer now directly owns 172,909 shares of the company's stock, valued at $4,320,995.91. The trade was a 1.89% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Parth Mehrotra sold 15,100 shares of the company's stock in a transaction on Wednesday, April 30th. The shares were sold at an average price of $23.33, for a total transaction of $352,283.00. Following the sale, the chief executive officer now owns 454,281 shares of the company's stock, valued at $10,598,375.73. This represents a 3.22% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 51,579 shares of company stock valued at $1,226,367. Insiders own 10.70% of the company's stock.
Institutional Trading of Privia Health Group
A number of institutional investors have recently modified their holdings of PRVA. Rhumbline Advisers raised its position in Privia Health Group by 1.3% during the 4th quarter. Rhumbline Advisers now owns 287,200 shares of the company's stock valued at $5,615,000 after purchasing an additional 3,658 shares during the last quarter. Barclays PLC increased its stake in shares of Privia Health Group by 240.3% during the third quarter. Barclays PLC now owns 224,018 shares of the company's stock valued at $4,079,000 after buying an additional 158,188 shares during the period. Choreo LLC raised its holdings in shares of Privia Health Group by 8.7% during the fourth quarter. Choreo LLC now owns 21,841 shares of the company's stock valued at $425,000 after acquiring an additional 1,752 shares in the last quarter. PNC Financial Services Group Inc. lifted its stake in Privia Health Group by 8.0% in the fourth quarter. PNC Financial Services Group Inc. now owns 7,169 shares of the company's stock worth $140,000 after acquiring an additional 533 shares during the period. Finally, Versor Investments LP purchased a new stake in Privia Health Group in the fourth quarter worth $721,000. 94.48% of the stock is currently owned by hedge funds and other institutional investors.
Privia Health Group Company Profile
(
Get Free ReportPrivia Health Group, Inc operates as a national physician-enablement company in the United States. The company collaborates with medical groups, health plans, and health systems to optimize physician practices, enhance patient experiences, and reward doctors for delivering care in-person and virtual settings.
Recommended Stories
Before you consider Privia Health Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Privia Health Group wasn't on the list.
While Privia Health Group currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
